Introduction
============

A central event in the pathogenesis of Alzheimer\'s disease (AD) is the deposition of amyloid β (Aβ) 1--40 and Aβ1--42 peptides generated by proteolytic cleavage by β- and γ-secretase from a larger membrane-bound protein, the amyloid precursor protein (APP).^[@bib1]^ APP and the secretases are integral transmembrane proteins dynamically sorted through the plasma membrane. Modulation of APP sorting through the membrane or altering APP cleavage by secretase enzymes could affect the regulation of Aβ production or processing.

Variants in two members of the vacuolar protein sorting 10 (VPS10) domain-containing receptor protein family, sortilin-related receptor (*SORL1*) and sortilin-related VPS10 domain-containing receptor 1 (*SORCS1*), are associated with late-onset AD presumably through effects on APP sorting and cleavage.^[@bib2],\ [@bib3],\ [@bib4]^ The VPS10 domain-containing receptor protein family contains five type I membrane homologs (SORL1, sortilin (SORT1), SorCS1, SorCS2 and SorCS3),^[@bib5],\ [@bib6],\ [@bib7],\ [@bib8],\ [@bib9]^ that are expressed in the central nervous system. All contain a single Vps10p-D situated at the N-terminus of their luminal/extracellular moiety. The VPS10 motif functions as a sorting receptor in the Golgi compartment required for the intracellular sorting and delivery of proteins, including APP. In SORT1, also known as neurotensin receptor-3, the Vps10p-D makes up the entire luminal extracellular part of the receptor, but the other four receptors have additional modules. In SORL1, the Vps10p-D is followed by five low-density lipoprotein receptor class B repeats flanked by an epidermal growth factor precursor-type repeat, a cluster of 11 low-density lipoprotein receptor class A repeats and 6 fibronectin type-III repeats. The mutually highly homologous SorCS1, SorCS2 and SorCS3 contain a leucine-rich segment between the Vps10p-D and the transmembrane domain. Structure prediction of the leucine-rich segment suggests a beta-sandwich fold and relates the domain to the immunoglobulin-like fold (E-set) superfamily. Following the extracellular and transmembrane segment, each receptor carries a short (40--80 amino acids) cytoplasmic domain comprising typical motifs for interaction with cytosolic adaptor molecules. In genomic DNA, members of this family are large with many exons but the coding sequence lengths are usually \<3700 nucleotides. Very large introns (introns 1--2) typically separate the exons encoding the VPS10 domain; the remaining exons are separated by much smaller introns. Exons 1--3 encode the VPS10 domain.

Previously, we demonstrated that SORL1 modulates the translocation and retention of APP in subcellular compartments, which are less favorable for secretase processing, thereby reducing the extent of proteolytic breakdown into both amyloidogenic and non-amyloidogenic products.^[@bib3]^ Furthermore, we showed that under-expression of *SORL1* leads to overexpression of Aβ and an increased risk of AD. Subsequently, we demonstrated that genetic variation in *SORCS1* also influences AD risk, cognitive performance, APP processing and Aβ40 and Aβ42 levels through an effect on γ-secretase processing of APP.^[@bib2],\ [@bib10]^ Overexpression of SorCS1 reduced Aβ40 and Aβ42 levels, whereas suppression of SorCS1 increased γ-secretase processing of APP. The association of *SORL1* with AD has been supported by a meta-analysis of Caucasian and Asian data sets that included a total of 12 464 cases and 17 929 controls^11^ and has been further validated in various ethnic groups, including African Americans, Israeli Arabs and Caribbean Hispanics, although with some degree of allelic heterogeneity.^[@bib3],\ [@bib11],\ [@bib12],\ [@bib13],\ [@bib14],\ [@bib15],\ [@bib16],\ [@bib17],\ [@bib18]^ In addition, these data are supported by a study in which overexpression of SorCS1cβ-myc in cultured cells caused a significant reduction in Aß generation, whereas, conversely, endogenous murine Aß40 andAß42 levels were increased in the brains of Sorcs1 hypomorphic mice.^[@bib19]^

We hypothesized that variants in other members of the sortilin-related VPS10 domain containing receptor family, namely *SORCS2*, *SORCS3* and *SORT1*, would also be associated with AD risk either independently or through epistatic effects. These homologous genes are expressed in different brain regions with different subcellular localisations,^[@bib20],\ [@bib21],\ [@bib22]^ but there are many brain regions, such as the hippocampus, in which these genes are co-expressed albeit at low levels.^[@bib20]^

We conducted single-marker association and epistasis analyses of all the five homologous genes in a large Caucasian case-control data set, with sufficient power to detect modest effect sizes and interactive effects. In addition, we conducted microarray gene expression analyses and γ-secretase assays for *SORCS1*, *SORCS2*, *SORCS3* and *SORT1.*

Participants and methods
========================

Ethics statement
----------------

Informed consent was obtained from all the participants using procedures approved by institutional review boards at each of the clinical research centers collecting human subjects for the ADGC project.

Participants
------------

The data set included 11 840 cases and 10 931controls from the ADGC data set.^[@bib23]^ The clinical characteristics are summarized in [Table 1](#tbl1){ref-type="table"}. The diagnoses of 'probable\' or 'possible\' AD were defined based on the National Institute of Neurological and Communication Disorders and Stroke--Alzheimer\'s Disease and Related Disorders Association (NINCDS-ADRDA) diagnosis criteria at clinics specializing in memory disorders or in clinical investigations. Persons were classified as 'controls\' when they were without cognitive impairment or dementia at last visit.

Genotyping
----------

HapMap2-imputed genotypic data for single nucleotide polymorphisms (SNPs) in *SORCS1* (*n*=648), *SORCS2* (*n*=740), *SORCS3* (*n*=742), *SORL1* (*n*=160) and *SORT1* (*n*=40) was obtained from the previously published genome-wide association study.^[@bib23]^ The SNPs assessed included both intronic and exonic SNPs. The *SORCS1* SNPs were not identical to the SNPs assessed in our previous study, which had been selected based on previous reports.^[@bib2]^ Details regarding apolipoprotein E (*APOE*) genotyping are described in the [Supplementary methods](#sup1){ref-type="supplementary-material"}.

Cell culture and transfection
-----------------------------

Using HEK293 cell lines, reverse transcriptase--PCR (RT--PCR) and western analysis were used to detect all five VPS10 proteins and to verify the knockdown and specificity of each short hairpin RNA (shRNA) as previously described.^[@bib2]^ The corresponding shRNA DNA sequences are shown in [Supplementary Table 3](#sup1){ref-type="supplementary-material"}.

APP-GV Assay
------------

The γ-secretase activity and nuclear translocation of the APP/Fe65/TIP60 protein complex was monitored with the APP-GV assay.^[@bib24]^ The APP-GV assay is a luciferase-based assay^[@bib24]^ consisting of the *APP* gene\'s C-terminus (AICD) fused to a transcription factor composed of the GAL4 DNA-binding domain with VP16 transcriptional activator (GV). In addition, the AICD fragment is fused to the GV domains as a positive control of AICD generation and allows for the evaluation of the AICD-specific contribution to the observed modulation in the APP-GV assay. Briefly, SorCS2 cDNA or SorCS2 shRNAs transiently transfected were evaluated in either the APP-GV or the AICD-GV assay, as previously described^[@bib24]^ in the HEK293 cell line. SorCS3 cDNA or SorCS3 shRNAs, and SORT1 cDNA or SORT1 shRNAs, were evaluated in a similar fashion.

Microarray gene expression and quantitative RT--PCR
---------------------------------------------------

Expression profiling was performed separately for the cerebellum, parietal-occipital neocortex and amygdala regions from 19 AD and 10 control brains from the New York Brain Bank ([www.nybb.hs.columbia.edu](http://www.nybb.hs.columbia.edu)). This three-region approach allowed us to enhance the signal-to-noise ratio^[@bib25]^ and to determine those changes in expression that are specific for late-onset AD and consistent with the distribution of AD pathology. For the expression profiling of AD and control brains, the Affymetrix GeneChip Human Exon 1.0 ST Arrays (Affymetrix, Santa Clara, CA, USA) were used. Frozen brain tissue was ground over liquid nitrogen and stored at −80 °C until use. Total RNA was extracted and purified using the TRIzol Plus RNA purification kit (Invitrogen, Life Technologies, Grand Island, NY, USA). All RNA preparations were analyzed using an Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA; RNA 6000 nano-kit) to determine RNAquantity/quality and only samples with RNA integrity number \>8 were used in the subsequent RNA amplification and hybridization steps. The Genechip expression two-cycle target labeling kit (Affymetrix) was used for all samples according to Affymetrix\'s protocols. Briefly, the procedure consists of an initial ribosomal RNA reduction step and two cycles of reverse transcription followed by *in vitro* transcription. For each sample, 1 μg of total RNA is initially subjected to removal of ribosomal RNA using the RiboMinus Transcriptome Isolation Kit (Invitrogen) and spiked with Eukaryotic PolyA RNA controls (Affymetrix). The ribosomal RNA-depleted fraction was used for cDNA synthesis by reverse transcription primed with T7-random hexamer primers, followed by second strand synthesis. This cDNA served as the template for *in vitro* transcription to obtain amplified antisense cRNA. Subsequently, cRNA from the first round was reverse transcribed using random primers to obtain single-stranded sense DNA. In this second reverse transcription, dUTP (2′-deoxyuridine, 5′-triphosphate) is incorporated into the DNA to allow for subsequent enzymatic fragmentation using a combination of UDG (uracil-DNA glycosylase) and APE1 (apyrimidinic endonuclease 1). All reverse and *in vitro* transcription steps were performed using the GeneChip WT cDNA synthesis and amplification Kit (Affymetrix). The resulting fragmented DNA was labeled with Affymetrix DNA Labeling Reagent. Labeled fragmented DNA was hybridized to Affymetrix Human Exon 1.0 ST arrays, washed and stained using the GeneChip Hybridization, Wash and Stain Kit (Affymetrix). Fluorescent images were recorded on a Genechip scanner 3000 and analyzed with the GeneChip operating software.

Significant results obtained from the microarray study were validated by quantitative RT--PCR using the same set of AD and control samples. Total RNA (1 μg) from of the amygdala region was used to generate cDNAs using the AffinityScript first-strand synthesis kit (Agilent Stratagene, CA, USA). RT--PCR primers were designed for three randomly selected exons of SorCS3 (10, 17 and 21). The housekeeping gene, TBP (TATA-binding protein) , was used as the endogenous control; and samples were analyzed in triplicate. The primers used in the quantitative RT-PCR are available from [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. Real-time RT-PCR was done using SYBR Green reagent (TaKaRa Mirus Bio, Madison, WI, USA) on an ABI7500 system (Applied Biosystems, Foster City, CA, USA).

Statistical methods
-------------------

Extensive quality review of SNPs and samples were previously completed.^[@bib23]^ Then multivariate logistic regression analyses in PLINK (<http://pngu.mgh.harvard.edu/~purcell/plink/>) were used to assess additive genotypic and allelic associations with AD risk in the case-control data sets, and generalized estimating equation models were used for family-based data sets. All models were first adjusted for age at examination, sex and population stratification and subsequently for *APOE-ɛ4* (additive effect) as well. For adjustment for population stratification, the first two, three or four estimated principal components were used, as described previously.^[@bib23]^ Logistic generalized estimating equation models^[@bib26],\ [@bib27]^ were used to evaluate association in the family-based data sets, using the same adjustments. Then, a meta-analysis of the individual study results was performed using inverse variance weights for the effect estimates as implemented in METAL (<http://www.sph.umich.edu/csg/abecasis/Metal/>). In order to take linkage disequilibrium (LD) between the markers into account, the *P*-value threshold for multiple testing correction was, in both single-marker and epistasis analyses, determined by applying the algorithm by Li and Ji.^[@bib28]^ As this was a candidate gene study with the *a priori* hypothesis of an association between each of the explored genes and AD, the calculation was done separately for each gene.

Epistasis
---------

Using only the SNPs that were associated with AD in the single-marker analyses (*P*⩽0.05), we tested for an interaction between SNPs in the five homologous genes. The analysis was carried out using PLINK (<http://pngu.mgh.harvard.edu/~purcell/plink/>) adjusting for population stratification. The model based on generalized estimating equations yields a list of SNP-by-SNP comparisons with beta coefficients and *P*-values. Based on the number of independent interactions tested, we accepted a *P*-value of ⩽0.0001 as statistically significant. As described above, LD between the markers was taken into account applying the algorithm by Li and Ji.^[@bib28]^

Statistical analysis for the gene expression and quantitative RT--PCR data
--------------------------------------------------------------------------

To determine in which genes expression levels differ between affected and unaffected brain regions, as well as between AD and control brains, we performed both within- and between-group factors\' analysis of variance using PARTEK GENOMICS SUITE 6.4 (<http://www.partek.com/partekgs>). Before the expression analysis, we log~10~-transformed the Rank invariant normalized expression data. False discovery rate was used to account for the error in multiple comparisons. The real-time RT--PCR data were analyzed by the comparative CT method integrated in the DataAssist Software (Life Technologies).^[@bib29]^

Statistical analysis for the cell biology assays
------------------------------------------------

Mean expression levels were compared by analysis of variance with *post hoc* correction using Graphpad Statistical software (Graphpad, Inc., San Diego, CA, USA). All data were normalized to transfection efficiency (for example, green fluorescent protein) and then to the control values on each plate for every assay to allow for comparisons across experiments.

Results
=======

Single-marker analyses
----------------------

[Table 1](#tbl1){ref-type="table"} shows the characteristics of the study populations. In all, 15 SNPs in *SORL1*, 23 SNPs in *SORCS1*, 18 SNPs in *SORCS2* and 12 SNPs in *SORCS3* were associated with AD ([Table 2](#tbl2){ref-type="table"}). These SNPs belonged to distinct LD blocks in these genes ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). All SNPs in *SORL1* reached statistical significance after correction for multiple testing and taking LD between the markers into account. One of these SNPs, rs1784933, corresponds to SNP26 in the original study by Rogaeva *et al.*^[@bib3]^ and is located 6 kb from SNP 25, which is part of one of the two SORL1 clusters that have been repeatedly associated with AD in different ethnic groups.^[@bib3],\ [@bib18]^ The SNPs in *SORCS1*, *SORCS2* and *SORCS3* were close, but not statistically significant. Interestingly, in line with previous reports,^[@bib2]^ most of the significant SNPs in *SORCS1* and *SORCS2* are located in intron 1, which is adjacent to the exons encoding the VPS10 domain. In addition, in all the four homologs (*SORL1*, *SORCS1*, *SORCS2*, *SORCS3*) some of the disease-associated SNPs were close to splice sites ([Table 2](#tbl2){ref-type="table"}). None of the genotyped SNPs in *SORT1* were significantly associated with AD ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}).

Epistasis analysis
------------------

Upon testing for epistatic effects between the SNPs that were associated in the single-marker analyses ([Table 3a](#tbl3){ref-type="table"}), 34 pairs of SNPs showed epistatic effects at a *P*-value of \<0.01. The vast majority (*n*=26 pairs) included a specific LD block in *SORCS3* with two specific LD blocks in *SORCS2* ([Table 3](#tbl3){ref-type="table"}, [Figures 1a and b](#fig1){ref-type="fig"}). Consistent with the single-marker analyses, the interacting SNPs were located in introns 1 and 2 ([Table 3](#tbl3){ref-type="table"}, [Figure 1](#fig1){ref-type="fig"}), adjacent to the exons coding for the VPS10 domain. The epistasis β for these *SORCS2/SORCS3* interactions ranged from −0.94 to 0.94, reflecting larger effects (additive) than the single-marker effects (−0.15\<β\<0.20).

Eight pairs resembled additional epistatic effects between *SORCS1/SORCS3* and between *SORCS1/SORCS2* ([Table 3b](#tbl3){ref-type="table"}). Of note, the single *SORCS3* SNP (rs1670036) interacting with *SORCS1* is located in the specific LD block also showing interaction with *SORCS2* ([Figure 1a](#fig1){ref-type="fig"}), and again all SNPs constituting the LD block in *SORCS1* are located in introns 1 and 2 ([Figure 1c](#fig1){ref-type="fig"}) adjacent to the exons encoding the VPS10 domain. The epistasis β for these *SORCS1/SORCS3* and *SORCS1/SORCS2* interactions ranged from −0.39 to 0.40, again reflecting larger effects (additive) than the corresponding single-marker analyses (−0.15\<β\<0.20). Although the *P*-values for epistatic effects just missed the multiple testing threshold of 0.0001, the number of significant interactions was clearly higher than expected by chance (expected *SORCS2/SORCS3* interactions: 10.8). Forest plots for the SNPs with epistatic effects or strongest individual associations with AD (rs7665496, rs6840423, rs7684383, rs4234804, rs1670036, rs1792124, rs12248379, rs13110208) are shown in [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}.

Microarray gene expression and quantitative RT-PCR analyses
-----------------------------------------------------------

Microarray expression analyses showed lower expression of SorCS3 in AD brains compared with control brains (mean gene expression intensity: 4.17±0.43 vs 5.03±0.49 (*P*=5.1E−5; [Figure 2a](#fig2){ref-type="fig"}), in line with what we had previously observed in *SORL1* and *SORCS1*.^[@bib2],\ [@bib3]^ To validate the significant results of the Affymetrix array, we conducted a quantitative RT-PCR for the *SORCS3* gene, using brain tissue from the amygdala region. Calculation of the fold change rate with the Relative Quantitation method of DataAssist software confirmed the results of the expression array for all the three investigated *SORCS3* exons. Compared with the control samples, the AD samples showed significantly reduced expression of exons 10, 17 and 21 of *SORCS3*; 87% (*P*=0.012), 74% (*P*=0.003) and 83% (*P*=0.003), respectively ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). Notably, these findings were also validated by comparison with publicly available gene expression results (188 cases, 176 controls, *P*\<0.0001, <http://labs.med.miami.edu/myers/>).^[@bib30]^ We did not find a significant difference between AD and controls in the expression levels of *SORCS2* or *SORT1* ([Figures 2b](#fig2){ref-type="fig"} and [c](#fig2){ref-type="fig"}). There was no significant difference in the expression levels between AD and control brains in brain tissue from regions unaffected by the disease process (occipital lobe, cerebellum) for any of the homologs.

Cell culture and transfection
-----------------------------

cDNA transfection of Vps10 family members in Hek 293 cells demonstrated a significant (0.01⩽*P*⩽0.05) decrease of γ-secretase (APP-GV), whereas there was no effect on the AICD-GV translocation assay ([Figure 3](#fig3){ref-type="fig"}).

γ-Secretase processing
----------------------

In HEK293 cells ([Figure 4](#fig4){ref-type="fig"}), 4/4 SorCS2-shRNAs, 3/3 SorC3-shRNAs and 2/3 SORT1-shRNAs caused a significant increase greater than threefold in APP processing (from *P*\<0.001 to *P*\<0.05) as compared with the result with the scrambled shRNA (analysis of variance with Bonferroni correction) while not affecting the nuclear translocation of the control AICD-GV only-fragment.

Discussion
==========

Taken together with previous studies,^[@bib2],\ [@bib3]^ the findings here indicate that variants in *SORL1*, *SORCS1*, *SORCS2* and *SORCS3* of the VPS10-d receptor family are associated with AD risk. The results are consistent with previous studies showing associations between the SNPs in *SORL1* and *SORCS1* with AD^[@bib2],\ [@bib3],\ [@bib11],\ [@bib13],\ [@bib14],\ [@bib15],\ [@bib16],\ [@bib18]^ and with cognitive performance.^[@bib10]^ Similar to previous reports, the associated SNPs in *SORCS1*, *SORCS2* and *SORCS3* were mostly located in introns 1--3, implicating the VPS10 domain.

The effect sizes of the associated SNPs were small (β: −0.45 to 0.36), but this is consistent with previous observations for the homologous genes *SORL1* and *SORCS1*^[@bib2],\ [@bib3],\ [@bib18]^ as well as all recently detected novel AD susceptibility loci identified by large genome-wide association studies.^[@bib23],\ [@bib31],\ [@bib32],\ [@bib33],\ [@bib34]^

The epistasis models of SNPs significant in single-marker analyses further revealed pairwise SNP associations between specific LD blocks in the highly homologous *SORCS1*, *SORCS2* and *SORCS3*. One single LD block in *SORCS3* showed epistasis with both a single LD block in *SORCS1* and two specific LD blocks in *SORCS2*. In addition, the same two regions of *SORCS2* and *SORCS3* interacted. Of note, the epistasis β ranging from −0.94 to 0.94 reflected larger effects (additive) than the corresponding single-marker analyses (−0.15\<β\<0.20), and the interacting SNPs are almost exclusively located in introns 1 and 2, adjacent to the exons encoding the VPS10 domain. This region has also been demonstrated to include the majority of disease-associated SNPs for both *SORCS1* and *SORL1*.^[@bib2],\ [@bib3],\ [@bib10],\ [@bib18],\ [@bib20]^ Our findings indicate that there are sequences within these specific LD blocks that are biologically important and that are interacting. The mechanism underlying these interactions is presently unclear. It could arise from direct interaction between the homologs, interactions with a mutual binding partner or interactions with a common substrate, such as APP or APP-CTF. However, it could also result from quite remote interactions that do not require a first- or second-order interaction between these proteins.

Suppression of SORCS2, SORCS3 or SORT1 increased γ-secretase processing of APP, findings consistent with reported effects by SORL1 and SORCS1 on γ-secretase processing of APP and changes in Aβ40 and Aβ42 levels.^[@bib2],\ [@bib3]^ Although SorCS3 and SorCS1 do not convey trans-Golgi network to late endosome sorting,^[@bib35],\ [@bib36]^ SORT1 is---similar to SORL1---also capable of mediating sorting of ligands from the trans-Golgi network to late endosomes or lysosomes.^[@bib22]^ Interestingly, sortilin-mediated endocytosis has been shown to determine levels of progranulin involved in frontotemporal dementia.^[@bib37]^ Results from the current genome-wide association studies suggest that other genes *PICALM*, *BIN1* and *CD2AP*, modulate intracellular trafficking of cell surface proteins. Thus, it is appears that in addition to their effect on γ-secretase processing of APP, some members of the VPS10-d receptor family exert their effect on AD through modulation of APP trafficking.

Reduced expression of SORCS3 may be a secondary effect of the disease, but it is consistent with the γ-secretase assays, which indicated that suppression of SORCS3 activates Aβ production. If correct, this would provide a potential explanation for how downregulation of SORCS3 might increase risk for AD. We are unable to see any difference in the expression of *SORCS2* and *SORT1*. However, we cannot yet exclude the possibility that this was the result of the small sample size or chosen phenotype. In a previous study by Mufson *et al.*,^[@bib38]^ SORT1 levels were---consistent with our findings---not associated with clinical diagnosis or antemortem cognitive test scores. However, there was an association with severity of neuropathology by Braak and NIA-Reagan diagnoses.

The significant strengths of this study are the large sample size, allowing us to detect small effects and explore epistasis. Limitations include that the SNPs assessed were derived from available genome-wide arrays. Thus, they do not cover the complete genetic variation in these genes, and it is possible that there are additional disease-associated markers that have not been genotyped. It is also possible that we lacked the power to detect additional disease-associated markers or interactions of SNPs with lower allele frequencies or effect sizes.

Taken together, our results indicate that in addition to *SORL1* and *SORCS1*, the variants in other members of the VPS 10-D receptor family (*SORCS2*, *SORCS3* and *SORT1)* are associated with AD either independently or through epistatic mechanisms.
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![Black arrows: (**a**) The linkage disequilibrium (LD) block in sortilin-related VPS10 domain-containing receptor 3 (*SORCS3*) showing significant interaction with (**b**) two specific LD blocks in *SORCS2* and (**c**) one specific LD block in *SORCS1*. Red arrows: Additional single nucleotide polymorphisms (SNPs) showing epistasis between *SORCS2* and *SORCS3*. (**a**) The single LD block in *SORCS3* showing epistasis with two specific LD blocks in *SORCS2* ([Figure 3b](#fig3){ref-type="fig"}) and one specific LD block in *SORCS1* ([Figure 3c)](#fig3){ref-type="fig"}. (**b**) The two specific two LD blocks in *SORCS2* (black arrows) showing epistasis with *SORCS3*, and SNPs showing in addition epistasis with *SORCS1* (red arrows). (**c**) The specific LD block in *SORCS1* (black arrows) showing epistasis with the specific LD block in *SORCS3*, and SNPs showing epistasis with SNPs in *SORCS2* (red arrows).](tp201313f1){#fig1}

![(**a**) View of sortilin-related VPS10 domain-containing receptor 3 (*SORCS3*) exon expression profile in 19 Alzheimer\'s disease (AD; red triangles) and 10 control (CTRL; blue squares) amygdala tissue. Each triangle dot represents least squares mean expression of an exon in AD tissue; each square dot represents least squares mean expression of an exon in control tissue. The mean gene expression intensity of AD vs controls was 4.17±0.43 vs 5.03±0.49 (*P*=5.1E-5) across all exons. (**b**) View of *SORCS2* exon expression profile in 19 AD (red triangles) and 10 control (blue squares) amygdala tissue. Each triangle dot represents least squares mean expression of an exon in AD tissue; each square dot represents least squares mean expression of an exon in control tissue. The mean gene expression intensity of AD vs controls was 5.29±0.33 vs 5.08±0.32 (*P*=0.12) across all exons. (**c**) View of sortilin 1 (*SORT1*) exon expression profile in 19 AD (red triangles) and 10 control (blue squares) amygdala tissue. Each triangle dot represents least squares mean expression of an exon in AD tissue; each square dot represents least squares mean expression of an exon in control tissue. The mean gene expression intensity of AD vs controls was 9.43±0.38 vs 9.21±0.39 (*P*=0.17) across all exons.](tp201313f2){#fig2}

![cDNA overexpression in transfected HEK293 cells. AICD, *APP* gene\'s C-terminus; APP, amyloid precursor protein; GV, GAL4 DNA-binding domain with VP16 transcriptional activator; SORCS, sortilin-related VPS10 domain-containing receptor; SORLA, sortilin-related receptor.](tp201313f3){#fig3}

![γ-Secretase activity and nuclear translocation of amyloid precursor protein (APP) assays with sortilin-related VPS10 domain-containing receptor 2 (*SORCS2*), *SORCS3* or *SORT1* short hairpin RNAs (shRNAs). Both the APP-GV (GAL4 DNA-binding domain with VP16 transcriptional activator) and *APP* gene\'s C-terminus (AICD)-GV assay were performed in HEK293 cells. The data from *SorCS2*, *SorCS3* or sortilin 1 (*SORT1*) shRNA was normalized to either APP-GV only or AICD-GV with the scrambled sequence shRNA (shRNA-scrambled), which was included as a negative control. The data are representative for the assays, were performed in ⩾3 experiments in replicates of eight samples per condition (96-well format, s.d. bars are shown, \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001 as compared with APP-GV only (analysis of variance, Bonferroni\'s correction).](tp201313f4){#fig4}

###### Characteristics of the study sample

  *Characteristics*                             
  -------------------------------------- -------------
  Number of cases with AD                   11 840
  Number of controls                        10 931
  Age at Onset for AD cases (s.d.)        74.55 (6.8)
  Age at last exam for controls (s.d.)    76.26 (7.2)
  Proportion of females                     59.66%
                                                
  *Frequency of APOE e4+*                
   Cases                                     0.38
   Controls                                  0.14
                                                
  *Frequency of APOE e4−*                
   Cases                                     0.62
   Controls                                  0.86

Abbreviation: AD, Alzheimer\'s disease; APOE, apolipoprotein E.

###### SNPs in *SORL1, SORCS1 SORCS2* and *SORCS3* associated with AD: (a) SNPs in *SORL1*, (b) SNPs in *SORCS1*, (c) SNPs in *SORCS2*, (d) SNPs in *SORCS3*

  *(a)*                                                                                                        
  ------------ ---- ------------- --- --- -------- --------- -------- ---------- ------- --------------------- ------
  rs7946599    11   121 423 640    a   g  0.0155   −0.4545   0.1027    9.66E-06  20131   Intron 16             1006
  rs2298814    11   121 424 882    a   g  0.0157   −0.4234   0.0916    3.76E-06  23821   Intron 17             64
  rs6589885    11   121 426 042    a   g  0.0162   −0.4004   0.0851    2.57E-06  23821   Intron 18             15
  rs7131432    11   121 426 870    a   t  0.0165   −0.3804   0.0811    2.75E-06  23821   Intron 18             843
  rs720099     11   121 433 793    t   c  0.9829   0.3607    0.0766    2.51E-06  23821   Intron 21             3427
  rs11218342   11   121 434 428    t   c  0.9829   0.3575    0.0761    2.60E-06  23821   Intron 21             3221
  rs11218343   11   121 435 587    t   c  0.9828   0.3539    0.0755    2.72E-06  23821   Intron 21             2062
  rs1784919    11   121 439 665    t   c  0.0172   −0.3586   0.0752    1.88E-06  23821   Intron 22             1201
  rs1792124    11   121 441 520    a   g  0.0172   −0.359    0.0752    1.83E-06  23821   Intron 23             541
  rs3781835    11   121 448 254    a   g  0.0173   −0.3501   0.0751    3.14E-06  23821   Intron 23             145
  rs3781838    11   121 453 517    t   g  0.9825   0.3506    0.0754    3.29E-06  23821   Intron 25             650
  rs12272618   11   121 460 324    t   c  0.9821   0.3536    0.0754    2.74E-06  23821   Intron 29             225
  rs2276412    11   121 460 846    t   c  0.018    −0.3531   0.0752    2.64E-06  23821   CDS-synon (exon 30)    
  rs7939826    11   121 468 256    t   c  0.0198   −0.3463   0.0738    2.69E-06  23821   Intron 32             1775
  rs1784933    11   121 489 416    a   g  0.9532   0.216     0.0606    0.000363  21455   Intron 41             67

  *(b)*                                                                                             
  ------------ ---- ------------- --- --- -------- --------- -------- ---------- ------- ---------- --------
  rs12258738   10   108 557 945    t   g  0.9754   −0.1415   0.0665   0.03328    23821    Intron 3  21 495
  rs12248379   10   108 562 008    t   g  0.1844   0.0761    0.0257   0.003058   23821    Intron 3  25 558
  rs17121613   10   108 563 116    t   g  0.8766   −0.0773   0.0304   0.01106    23821    Intron 3  26 216
  rs4917491    10   108 650 174    t   c  0.5952   −0.0405   0.0202   0.04463    23821    Intron 2  60 743
  rs7076579    10   108 653 167    t   c  0.5951   −0.04     0.0202   0.04719    23821    Intron 2  63 104
  rs7096260    10   108 653 483    a   g  0.5949   −0.0396   0.0201   0.04944    23821    Intron 2  62 788
  rs12356136   10   108 657 180    t   c  0.4006   0.0403    0.0203   0.04731    23821    Intron 2  59 091
  rs7895881    10   108 658 597    a   t  0.4002   0.0406    0.0204   0.04674    23821    Intron 2  57 674
  rs1004921    10   108 659 048    a   g  0.4      0.041     0.0204   0.04501    23821    Intron 2  57 223
  rs10884389   10   108 695 777    t   c  0.4129   −0.0388   0.0197   0.04886    23821    Intron 2  20 494
  rs10786997   10   108 704 547    a   g  0.5873   0.0401    0.0196   0.04094    23821    Intron 2  11 724
  rs11193127   10   108 706 022    a   g  0.4125   −0.0399   0.0196   0.04169    23821    Intron 2  10 249
  rs11193128   10   108 706 198    t   c  0.5876   0.0397    0.0196   0.04273    23821    Intron 2  10 073
  rs10884390   10   108 709 366    a   g  0.5877   0.0399    0.0196   0.04167    23821    Intron2   6905
  rs10884391   10   108 709 892    a   c  0.4124   −0.0406   0.0196   0.03801    23821    Intron 2  6379
  rs10786998   10   108 710 127    a   c  0.4124   −0.0408   0.0196   0.03737    23821    Intron 2  6144
  rs12245675   10   108 712 233    t   c  0.4116   −0.0413   0.0196   0.03543    23821    Intron 2  4038
  rs17276802   10   108 712 398    t   c  0.4117   −0.0414   0.0196   0.03474    23821    Intron 2  3873
  rs2149197    10   108 716 784    c   g  0.5884   0.0435    0.0196   0.0268     23821    Intron 1  446
  rs11193130   10   108 718 454    t   c  0.5875   0.0435    0.0196   0.02677    23821    Intron 1  2116
  rs4918282    10   108 862 741    a   g  0.4074   0.0651    0.0263   0.0134     20952    Intron 1  60 986
  rs10787010   10   108 862 960    a   g  0.6392   −0.061    0.0303   0.04421    17630    Intron 1  60 767
  rs11193209   10   108 890 136    t   c  0.9776   −0.1544   0.0746   0.03843    23821    Intron 1  33 591

  *(c)*                                                                                           
  ------------ --- ----------- --- --- -------- --------- -------- ---------- ------- ----------- --------
  rs11722747   4   7 314 043    a   g  0.1431   0.0554    0.0281   0.04836    23821    Intron 1   83 972
  rs4689707    4   7 326 199    t   c  0.1329   0.0663    0.0328   0.0434     19918    Intron 1   71 816
  rs3864203    4   7 328 416    a   g  0.6996   −0.0554   0.0265   0.03639    19918    Intron 1   69 599
  rs7665496    4   7 328 734    t   c  0.9063   −0.1045   0.0415   0.01184    19918    Intron 1   69 281
  rs7661158    4   7 329 065    a   g  0.6996   −0.0497   0.0239   0.03715    19918    Intron 1   68 950
  rs6840423    4   7 329 324    t   g  0.121    0.0849    0.0356   0.01723    19918    Intron 1   68 691
  rs3864202    4   7 329 426    a   g  0.7018   −0.049    0.0233   0.03506    19918    Intron 1   68 589
  rs16840053   4   7 330 676    a   g  0.1462   0.0778    0.0315   0.0136     19918    Intron 1   67 339
  rs13110208   4   7 353 052    t   c  0.5296   −0.0626   0.0241   0.009441   17630    Intron 1   44 963
  rs4689720    4   7 390 442    t   c  0.1019   −0.1178   0.0531   0.02643    16732    Intron 1   7573
  rs7684383    4   7 417 241    t   c  0.0403   −0.1429   0.069    0.03841    19633    Intron 2   19 159
  rs4234804    4   7 417 632    a   g  0.0396   −0.1509   0.0674   0.02505    20990    Intron 2   19 550
  rs6837589    4   7 419 276    t   c  0.1688   −0.0589   0.0277   0.03358    22439    Intron 2   21 194
  rs13105690   4   7 420 184    t   c  0.2742   −0.0599   0.0248   0.01552    19918    Intron 2   22 102
  rs4292336    4   7 420 785    a   g  0.8316   0.0546    0.0277   0.04904    22439    Intron 2   22 703
  rs17465564   4   7 622 347    a   g  0.9136   0.0861    0.04     0.03151    22439    Intron 3   17 708
  rs2214459    4   7 667 486    t   c  0.6948   −0.0519   0.0234   0.02645    21275    Intron 7   1288
  rs12233824   4   7 733 843    a   g  0.45     −0.04     0.0203   0.04877    23821    Intron 23  1206

  *(d)*                                                                                              
  ------------ ---- ------------- --- --- -------- --------- -------- --------- ------- ------------ --------
  rs12249460   10   106 605 440    a   g  0.0361   0.136     0.0585   0.01999   23821     Intron 2   2823
  rs6584629    10   106 608 435    a   g  0.0475   0.1038    0.0457   0.02303   23821     Intron 2   5818
  rs12259189   10   106 615 387    t   c  0.0474   0.0972    0.0458   0.03358   23821     Intron 2   12 770
  rs3976793    10   106 616 736    a   g  0.0474   0.0969    0.0458   0.03433   23821     Intron 2   14 119
  rs12262245   10   106 621 704    c   g  0.9529   −0.0941   0.046    0.04088   23821     Intron 2   19 087
  rs7086583    10   106 622 009    a   c  0.9529   −0.0929   0.046    0.04342   23821     Intron 2   19 392
  rs1670036    10   106 807 189    a   c  0.978    0.2082    0.0867   0.0164    23821     Intron 5   4 303
  rs749304     10   106 990 399    a   g  0.7655   −0.0469   0.0227   0.0391    23821    Intron 20   7392
  rs12263804   10   106 993 770    t   c  0.2348   0.0474    0.0227   0.03711   23821    Intron 20   10 763
  rs7920533    10   107 013 252    a   g  0.3247   0.0546    0.0221   0.01354   23821    Intron 23   588
  rs3750261    10   107 023 390    t   c  0.2396   0.045     0.0226   0.04653   23821      UTR-3      
  rs10884126   10   107 025 028    a   g  0.2397   0.0451    0.0226   0.04627   23821    NearGene-3   

Abbreviations: BP, base pair position; β, beta coefficient; CDS, coding sequence; CHR, chromosome; location, single nucleotide polymorphism (SNP) location; NUMOBS, number of subjects; s.e., standard error of beta coefficient; SORCS1, sortilin-related VPS10 domain-containing receptor 1; SORL1, sortilin-related receptor 1; UTR, untranslated rgion.

Based on the number of tests performed, a *P*-value of 0.0009 can be considered statistically significant.

Exons 1--16 encode the VPS10 domain.

Based on the number of tests performed, a *P*-value of 0.0002 can be considered statistically significant.

Exons 1--18 encode the VPS10 domain.

Based on the number of tests performed, a *P*-value of 0.0006 can be considered statistically significant.

###### Epistasis between two specific LD blocks in (a) *SORCS2* and *SORCS3*, and (b) *SORCS1/SORCS2* and *SORCS1/SORCS3*

  *(a)*                                                                                                                                                    
  ------------ ----------- ---- ---- --------- -------- --------- ----------------- ---- ------------- ---------- ------------- --- ----------- ---------- ----------
  rs749304      rs7665496   ac   gt  −0.2347   0.0731   0.00133    −−−−−−?−−−−??−−  10   106 990 399    *SORCS3*    Intron 20   4   7 328 734    *SORCS2*   Intron 1
  rs12263804    rs7665496   cc   tt  −0.2345   0.0731   0.00134    −−−−−−?−−−−??−−  10   106 993 770    *SORCS3*    Intron 20   4   7 328 734    *SORCS2*   Intron 1
  rs3750261     rs7665496   cc   tt  −0.2163   0.0723   0.00279    −−−−−−?−−−−??−−  10   107 023 390    *SORCS3*      UTR-3     4   7 328 734    *SORCS2*   Intron 1
  rs10884126    rs7665496   ac   gt  0.2153    0.0724   0.00292    ++++++?++++??++  10   107 025 028    *SORCS3*   Near gene-3  4   7 328 734    *SORCS2*   Intron 1
  rs749304      rs6840423   ag   gt  0.1592    0.061    0.00903    +−−+++?++++++−+  10   106 990 399    *SORCS3*    Intron 20   4   7 329 324    *SORCS2*   Intron 1
  rs12263804    rs6840423   cg   tt  0.1584    0.061    0.00936    +−−+++?++++++−+  10   106 993 770    *SORCS3*    Intron 20   4   7 329 324    *SORCS2*   Intron 1
  rs749304      rs7684383   ac   gt  −0.4259   0.125    0.00066    −−−−−+?−−−−??−−  10   106 990 399    *SORCS3*    Intron 20   4   7 417 241    *SORCS2*   Intron 2
  rs12263804    rs7684383   cc   tt  −0.4249   0.125    0.00067    −−−−−+?−−−−??−−  10   106 993 770    *SORCS3*    Intron 20   4   7 417 241    *SORCS2*   Intron 2
  rs10884126    rs7684383   ac   gt  0.4128    0.1224   0.00074    +++++−?++++??++  10   107 025 028    *SORCS3*   NearGene-3   4   7 417 241    *SORCS2*   Intron 2
  rs3750261     rs7684383   cc   tt  −0.4121   0.1223   0.00076    −−−−−+?−−−−??−−  10   107 023 390    *SORCS3*      UTR-3     4   7 417 241    *SORCS2*   Intron 2
  rs12262245    rs7684383   cc   gt  −0.7045   0.2318   0.00237    −−−−−+?−−−−??+−  10   106 621 704    *SORCS3*    Intron 2    4   7 417 241    *SORCS2*   Intron 2
  rs7086583     rs7684383   ac   ct  −0.7032   0.2317   0.00241    −−−−−+?−−−−??+−  10   106 622 009    *SORCS3*    Intron 2    4   7 417 241    *SORCS2*   Intron 2
  rs3976793     rs7684383   ac   gt  0.6954    0.2332   0.00287    ++++−−?++++??−+  10   106 616 736    *SORCS3*    Intron 2    4   7 417 241    *SORCS2*   Intron 2
  rs12259189    rs7684383   cc   tt  −0.6935   0.2333   0.00295    −−−−++?−−−−??+−  10   106 615 387    *SORCS3*    Intron 2    4   7 417 241    *SORCS2*   Intron 2
  rs6584629     rs7684383   ac   gt  0.6881    0.2349   0.00341    ++++−−?++++??−+  10   106 608 435    *SORCS3*    Intron 2    4   7 417 241    *SORCS2*   Intron 2
  rs12249460    rs7684383   ac   gt  0.9499    0.3247   0.00345    +++++−?+++−??−+  10   106 605 440    *SORCS3*    Intron 2    4   7 417 241    *SORCS2*   Intron 2
  rs749304      rs4234804   aa   gg  0.4236    0.125    0.00071    +++++−?++++??++  10   106 990 399    *SORCS3*    Intron 20   4   7 417 632    *SORCS2*   Intron 2
  rs10884126    rs4234804   aa   gg  −0.4137   0.1223   0.00072    −−−−−−?−−−−??−−  10   107 025 028    *SORCS3*   NearGene-3   4   7 417 632    *SORCS2*   Intron 2
  rs12263804    rs4234804   ca   tg  0.4225    0.125    0.00072    +++++−?++++??++  10   106 993 770    *SORCS3*    Intron 20   4   7 417 632    *SORCS2*   Intron 2
  rs3750261     rs4234804   ca   tg  0.413     0.1223   0.00073    ++++++?++++??++  10   107 023 390    *SORCS3*      UTR-3     4   7 417 632    *SORCS2*   Intron 2
  rs12262245    rs4234804   ca   gg  0.6971    0.2313   0.00258    +++++−?++++??−+  10   106 621 704    *SORCS3*    Intron 2    4   7 417 632    *SORCS2*   Intron 2
  rs7086583     rs4234804   aa   cg  0.6958    0.2312   0.00262    +++++−?++++??−+  10   106 622 009    *SORCS3*    Intron 2    4   7 417 632    *SORCS2*   Intron 2
  rs3976793     rs4234804   aa   gg  −0.6885   0.2327   0.00309    −−−−++?−−−−??+−  10   106 616 736    *SORCS3*    Intron 2    4   7 417 632    *SORCS2*   Intron 2
  rs12259189    rs4234804   ca   tg  0.6867    0.2328   0.00318    ++++−−?++++??−+  10   106 615 387    *SORCS3*    Intron 2    4   7 417 632    *SORCS2*   Intron 2
  rs6584629     rs4234804   aa   gg  −0.6823   0.2344   0.0036     −−−−++?−−−−??+−  10   106 608 435    *SORCS3*    Intron 2    4   7 417 632    *SORCS2*   Intron 2
  rs12249460    rs4234804   aa   gg  −0.9405   0.3241   0.00371    −−−−−+?−−−+??+−  10   106 605 440    *SORCS3*    Intron 2    4   7 417 632    *SORCS2*   Intron 2

  *(b)*                                                                                                                                                     
  ------------ ----------- ---- ---- --------- -------- ---------- ----------------- ---- ------------- ---------- ---------- ---- ------------- ---------- ----------
  rs10786998    rs1670036   aa   cc  0.4053    0.1506   0.007122    ?+−++++++−+++?+  10   108 710 127    *SORCS1*   Intron 2  10   106 807 189    *SORCS3*   Intron 4
  rs10884391    rs1670036   aa   cc  0.4048    0.1507   0.007238    ?+−++++++−+++?+  10   108 709 892    *SORCS1*   Intron 2  10   106 807 189    *SORCS3*   Intron 4
  rs11193130    rs1670036   ca   tc  0.3929    0.1509   0.009219    ?+−++++++−+++?+  10   108 718 454    *SORCS1*   Intron 1  10   106 807 189    *SORCS3*   Intron 4
  rs12245675    rs1670036   ca   tc  −0.3924   0.1512   0.009424    ?−+−−−−+−+−−−?−  10   108 712 233    *SORCS1*   Intron 2  10   106 807 189    *SORCS3*   Intron 4
  rs17276802    rs1670036   ca   tc  −0.392    0.1512   0.009515    ?−+−−−−+−+−−−?−  10   108 712 398    *SORCS1*   Intron 2  10   106 807 189    *SORCS3*   Intron 4
  rs10884389    rs1670036   ca   tc  −0.3898   0.1509   0.009817    ?−+−−−−−−+−−−?−  10   108 695 777    *SORCS1*   Intron 2  10   106 807 189    *SORCS3*   Intron 4
  rs11193209    rs2214459   cc   tt  −0.3988   0.1451   0.005997    +−++−??−+−?+−−−  10   108 890 136    *SORCS1*   Intron 1  4    7 667 486      *SORCS2*   Intron 7
  rs17121613    rs4689707   gc   tt  −0.2004   0.0747   0.007332    −−−−−−−++−−++−+  10   108 563 116    *SORCS1*   Intron 3  4    7 326 199      *SORCS2*   Intron 1

Abbreviations: A1, Allele 1; A2, Allele 2; Beta, beta coefficient; CHR, chromosome; DIR, direction of effect; location, single nucleotide polymorphism (SNP) LD, linkage disequilibrium; location; s.e., standard error of beta coefficient; SORCS1, sortilin-related VPS10 domain-containing receptor 1.

*P*-value cutoff for significance after correction for multiple testing: *P*=0.0001.

Exons 1--18 encode the VPS10 domain.
